Krystal Biotech, Inc.
krystalbio.comWhat Do They Do?
Sells VYJUVEK, a topical gene therapy for a rare skin disease, to specialty pharmacies, hospitals and specialty distributors, while developing gene therapies for other serious diseases.
10-K for FY2025, filed Feb 17, 2026Our first commercial product, VYJUVEK®, is now approved in the United States, the European Union (“EU”), and Japan for the treatment of…View ↗
Our development pipeline includes multiple clinical stage product candidates for the treatment of rare and serious diseases, and we are…View ↗
VYJUVEK is a redosable, off-the-shelf gene therapy designed to deliver two copies of the COL7A1 gene when applied topically, directly onto…View ↗
The Company sells VYJUVEK to a limited number of specialty pharmacy (“SPs”) providers that mix the medication to be administered at a…View ↗
How Do They Make Money?
Specialty pharmacies, hospitals and specialty distributors buy VYJUVEK; the company gets paid when the product is delivered to the customer.
10-K for FY2025, filed Feb 17, 2026The Company sells VYJUVEK to a limited number of specialty pharmacy (“SPs”) providers that mix the medication to be administered at a…View ↗
$389.1M
-
10-K for FY2025, filed Feb 17, 2026
$389.1M ↗
Who Are Their Customers?
The company sells VYJUVEK to specialty pharmacies, hospitals and specialty distributors. Specialty pharmacies mix the medicine for use in a healthcare professional’s office or at home, while hospitals and distributors deliver it for treatment in healthcare settings.
10-K for FY2025, filed Feb 17, 2026The Company sells VYJUVEK to a limited number of specialty pharmacy (“SPs”) providers that mix the medication to be administered at a…View ↗
10-K for FY2025, filed Feb 17, 2026
Following FDA approval in May 2023, the Company began commercial marketing and sales of VYJUVEK and began recognizing revenue in the third…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 53 cents of every revenue dollar as net income in FY2025 and turned 49 cents into free cash flow.
10-K for FY2025, filed Feb 17, 2026
$161.3MView ↗
10-K for FY2025, filed Feb 17, 2026
$204.8MView ↗
10-K for FY2025, filed Feb 17, 2026
$188.9MView ↗
How Are They Changing?
Who Do They Compete With?
Competes with Abeona Therapeutics, Castle Creek Biosciences, BridgeBio Pharma, Chiesi Farmaceutici, RHEACELL, Vertex Pharmaceuticals, ReCode Therapeutics, Spirovant Sciences, 4D Molecular Therapeutics, CSL, Takeda Pharmaceutical, Grifols, Arrowhead Pharmaceutical, Novo Nordisk, Alnylam Pharmaceuticals, Kamada, Sanofi, Peak Bio, Mereo BioPharma Group, and Wave Life Sciences
10-K for FY2025, filed Feb 17, 2026Corrective Approaches: We are aware of companies, Abeona Therapeutics Inc. and Castle Creek Biosciences, Inc., which are developing or have…View ↗
Loading...
